Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

IMP-29, a Novel IMP-Type Metallo-β-Lactamase in Pseudomonas aeruginosa

Katy Jeannot, Laurent Poirel, Marjorie Robert-Nicoud, Pascal Cholley, Patrice Nordmann, Patrick Plésiat
Katy Jeannot
aCentre National de la Résistance aux Antibiotiques, Laboratoire associé Pseudomonas aeruginosa, Hôpital Jean Minjoz, Besançon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Poirel
bService de Bactériologie-Virologie, INSERM U914 Emerging Resistance to Antibiotics, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine et Université Paris-Sud, K.-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marjorie Robert-Nicoud
aCentre National de la Résistance aux Antibiotiques, Laboratoire associé Pseudomonas aeruginosa, Hôpital Jean Minjoz, Besançon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Cholley
cService d'Hygiène Hospitalière et d'Epidémiologie, Hôpital Jean Minjoz, Besançon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Nordmann
bService de Bactériologie-Virologie, INSERM U914 Emerging Resistance to Antibiotics, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine et Université Paris-Sud, K.-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Plésiat
aCentre National de la Résistance aux Antibiotiques, Laboratoire associé Pseudomonas aeruginosa, Hôpital Jean Minjoz, Besançon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.05838-11
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Analysis of two clonally related multiresistant Pseudomonas aeruginosa isolates led to the identification of a novel IMP-type metallo-β-lactamase. IMP-29 was significantly different from the other IMP variants (the closest variant being IMP-5 with 93% amino acid identity). The blaIMP-29 gene cassette was carried by a class 1 integron in strain 10.298, while in strain 10.266 it was located in a rearranged DNA region on a 30-kb conjugative plasmid. Biochemical analysis confirmed that IMP-29 efficiently hydrolyzed carbapenems.

TEXT

Pseudomonas aeruginosa is a major opportunistic pathogen responsible for mild to severe nosocomial infections. Over the past decade, the emergence and spread of strains resistant to multiple antibiotics, including carbapenems, have become a serious clinical concern in many countries (12, 28). Resistance to carbapenems is usually due to mutational alteration of the imipenem-specific porin OprD but may also result from production of horizontally acquired β-lactamase genes (22). Most of the carbapenem-hydrolyzing enzymes (i.e., carbapenemases) found in P. aeruginosa belong to the Ambler class B of β-lactamases (27). These enzymes have been grouped into different types such as IMP, VIM, SPM, GIM, AIM, DIM, and NDM according to their amino acid sequences (4, 10). Of particular clinical importance are the IMP- and VIM-type metallo-β-lactamases (MBLs), which efficiently inactivate most of the antipseudomonal β-lactams except monobactams (7, 27). So far, 28 IMP-type β-lactamases have been identified in various Gram-negative species (K. Bush and G. Jacoby, http://www.lahey.org/Studies/).

Our study was initiated by the isolation of P. aeruginosa 10.266 (serotype O:12) from the blood culture of a 74-year-old male patient admitted in March 2010 to the medical intensive care unit of the teaching hospital of Besançon, France, for unstable diabetes associated with signs of pulmonary infection. The patient initially received a course of piperacillin-tazobactam, ciprofloxacin, rovamycin, and metronidazole for 16 days. Despite this aggressive therapy, he developed an acute respiratory distress syndrome, which prompted physicians to switch to imipenem and linezolid. This treatment failed, and the patient died from a septic shock 10 days later. A second serotype O:12 isolate, named 10.298, was recovered in June 2010 from a rectal swab of a 48-year-old male patient hospitalized for an acute myeloid leukemia in the hematology unit of the same hospital. The patient, who had no signs of infection, was not receiving antibiotics. Both isolates were highly resistant to all of the antipseudomonal β-lactams tested (ticarcillin, piperacillin-tazobactam, ceftazidime, cefepime, imipenem, and meropenem) except aztreonam (Table 1). They were also resistant to aminoglycosides (amikacin, tobramycin, and gentamicin) and ciprofloxacin but were susceptible to colistin (MIC of 0.5 μg/ml). Pulsed-field gel electrophoresis (PFGE) experiments using total DNA digested with endonuclease DraI (11) revealed that 10.266 and 10.298 were closely related (differing by only one band) and belonged to the same clone endemic in the hospital (23). The epidemiological link between the two patients carrying these bacteria could not be established (data not shown). The production of an MBL in both isolates was suggested by positive double-disk synergy tests between imipenem and EDTA (10 μl, 100 mM). Then, PCR experiments were carried out on purified DNA with primers specific for known MBL genes (blaIMP, blaVIM, blaNDM, blaSPM, blaAIM, blaDIM, and blaGIM) (15, 18, 21, 26). A blaIMP gene was amplified in both isolates, and sequencing identified a novel IMP-type MBL that was termed IMP-29 accordingly (http://www.lahey.org/Studies/).

View this table:
  • View inline
  • View popup
Table 1

Susceptibilities to β-lactams of P. aeruginosa and E. coli strains harboring gene blaIMP-29

Since blaIMP genes are usually associated with class 1 integron sequences, PCR experiments were performed with primers annealing to the 5′ conserved sequence (CS) and 3′ CS of class 1 integrons (3). This yielded a single amplicon in 10.266 (2.8 kb) and three amplicons in 10.298 (2.8, 2.1, and 1.2 kb, respectively). Sequencing of the 2.8-kb PCR products revealed the presence of the gene (blaPSE-1) encoding narrow-spectrum penicillinase PSE-1 (also termed CARB-2), flanked by two gene cassettes, aacA4 and aadA2, encoding the aminoglycoside-modifying enzymes AAC(6)′-Ib and ANT(3)′, respectively (Fig. 1A). Production of the two latter enzymes is consistent with the high resistance of the isolates to aminoglycosides. The 1.2-kb fragment from 10.298 contained the blaOXA-2 gene encoding narrow-spectrum oxacillinase OXA-2 (Fig. 1B), while the 2-kb fragment appeared to carry the blaIMP-29 gene located downstream of the aacA4 and dfrII gene cassettes encoding the AAC(6′)-Ib and dihydrofolate reductase enzymes, respectively (Fig. 1B).

Fig 1
  • Open in new tab
  • Download powerpoint
Fig 1

Schematic map of class 1 integrons identified in clinical strains 10.266 and 10.298. The genes and their transcriptional orientations are indicated by arrows. The 59-base elements are indicated by a solid circle. (A) Structure of class 1 integron identified in both 10.266 and 10.298. (B) Structures of the two integrons identified in P. aeruginosa 10.298. (C) Structure of the cloned region containing the blaIMP-29 gene from the plasmid pIMP266.

Sequence alignments showed that IMP-29 was quite distant from other IMP-type MBLs (88.6% and 83.6% amino acid sequence identities with IMP-1 and IMP-8, respectively). Its closest relatives were IMP-5, IMP-22, and IMP-16 with 93, 92, and 91% sequence identity, respectively (5, 16, 19).

Interestingly, PCR experiments failed to detect a class 1 integron structure associated with blaIMP-29 in strain 10.266. To get further insight into the genetic environment of that gene, the plasmid content of isolate 10.266 was analyzed (13). A plasmid of ca. 30 kb was detected, which was named pIMP266. The potential of pIMP266 for conjugative transfer was assessed between 10.266 and a rifampin-resistant P. aeruginosa strain, PU21 (9). Transconjugant PU21(pIMP266) was selected on Mueller-Hinton agar plates supplemented with 100 μg/ml ticarcillin and 200 μg/ml rifampin. All the clones tested exhibited a high resistance to ticarcillin, cefotaxime, ceftazidime, and cefepime, associated with a reduced susceptibility to piperacillin and almost unchanged susceptibility to aztreonam compared with PU21 (Table 1). Plasmid pIMP266 conferred a higher resistance to meropenem (64 μg/ml) and doripenem (64 μg/ml) than to imipenem (8 μg/ml). Similar results have been reported in P. aeruginosa PAO1, PAO4141 (an AmpC-deficient mutant of PAO1), and Escherichia coli transformed with plasmids carrying blaIMP-12, blaIMP-10, and blaIMP-6, respectively (6, 8, 25). No coresistance marker was transferred by plasmid pIMP266.

To identify the genetic environment of the blaIMP-29 gene on plasmid pIMP266, a Sau3AI library of pIMP266 DNA was cloned into the BamHI-restricted plasmid pK18 (Kmr). Transformants of E. coli DH5α were selected on Mueller-Hinton agar plates containing 100 μg/ml ampicillin and 30 μg/ml kanamycin. In comparison to recipient strain DH5α, all the recombinant clones tested displayed a high level of resistance to β-lactams except aztreonam (Table 1). Sequence analysis of the 3-kb insert from one of these clones (plasmid pK-IMP266) revealed that the blaIMP-29 gene was flanked by several partial gene sequences belonging to loci distantly located on the P. aeruginosa genome such as narK (nitrite transport, PA3876) and PA1212 (major facilitator superfamily [MFS] pump) (Fig. 1C). This complex genetic environment likely reflects multiple rearrangements of the region surrounding blaIMP-29. Supporting this notion, the presence of a truncated tniC/R gene (encoding the resolvase of Tn401-like transposons), the integrase gene intl1, and a core site (59-base element) upstream of blaIMP-29 indicated that blaIMP-29 was initially associated with a mobile class 1 integron structure.

Since the MICs of carbapenems for isolate 10.266 were much higher than those for transconjugant PU21(pIMP266), the presence of an additional resistance mechanism was suspected (Table 1), such as the alteration of the OprD porin (17, 22, 24). Sequencing of the oprD gene revealed a premature stop codon in isolate 10.266 leading to a truncated peptide of 295 amino acid residues instead of 443 (wild-type OprD of P. aeruginosa PAO1). In 10.298, the oprD gene was also interrupted prematurely, resulting in a polypeptide lacking the last 28 C-terminal amino acids of OprD. However, the impact of the latter deletion on the porin function is likely to be modest since the MICs of carbapenems were relatively similar for 10.298 and PU21(pIMP266) (Table 1).

In order to better evaluate the impact of IMP-29 on the levels of resistance to β-lactams, the blaIMP-29 gene was expressed into E. coli. An 822-bp PCR fragment carrying blaIMP-29 was amplified by using specific primers cloIMP266F (5′-GTCGCCCGAAAACAAAGTTA-3′) and cloIMP266R (5′-AACTGTCCAAGGAGCGTAGC-3′). Once purified through a High Pure PCR product column (Roche Diagnostics, France), the amplicon was cloned into plasmid vector pCRScript CampR (Agilent Technologies) and subcloned into pK18 to yield recombinant plasmid pK-IMP29. As expected, transformant DH5α(pK-IMP29) exhibited an increased resistance to all the β-lactams tested except aztreonam (Table 1). However, the resistance levels conferred by pK-IMP29 were 2 to 32 times lower than those provided by pK-IMP266, suggesting a difference in blaIMP-29 expression between the two recombinant plasmids. E. coli DH5α(pK-IMP29) remained susceptible to imipenem, meropenem, doripenem, and ertapenem according to the current CLSI breakpoints (Table 1) (2).

To determine the catalytic properties of IMP-29, kinetic studies were carried out as previously described (20). Briefly, IMP-29 was purified from crude extracts of E. coli DH5α(pK-IMP29) by two-step anion-exchange chromatography in a Q-Sepharose column, first at pH 5.4 and then at pH 7.4. Since no enzymatic data have been reported for IMP-5, the closest relative to IMP-29, IMP-1 was used as the reference enzyme. Overall, the hydrolytic activities of IMP-29 were lower than those of IMP-1, in particular toward cefotaxime (35-fold lower), ceftazidime (72-fold lower), and cefepime (70-fold lower) (Table 2). IMP-29 hydrolyzed carbapenems at similar rates that were close to (meropenem) or lower than (imipenem, 20-fold; ertapenem, 17-fold) that of IMP-1. These assays confirmed that the enzyme has virtually no activity on aztreonam.

View this table:
  • View inline
  • View popup
Table 2

Kinetic parameters for β-lactamases IMP-29 and IMP-1a

In conclusion, this work describes a novel transferable IMP variant acquired by an endemic O:12 clone. Both isolates were highly resistant to piperacillin because of production of penicillinase PSE-1 and to carbapenems as a result of alteration of porin OprD. While the characterization of IMP-29 was in progress, five other blaIMP-29-positive, clonally related P. aeruginosa isolates were identified from January to July 2011 in patients hospitalized in the hematology unit of the hospital in Besançon. All of these isolates possessed the pIMP266 plasmid. This indicates an ongoing nosocomial dissemination of the multidrug-resistant P. aeruginosa strain 10.266 with a potential risk of transfer of pIMP266 to other Gram-negative bacteria.

Nucleotide sequence accession numbers.The nucleotide sequence data reported in this work have been deposited in the GenBank database under accession numbers JQ041634 and HQ438058.

ACKNOWLEDGMENT

The National Reference Center for Antibiotic Resistance was funded by the French ministry of health (InVS).

FOOTNOTES

    • Received 3 October 2011.
    • Returned for modification 6 November 2011.
    • Accepted 15 January 2012.
    • Accepted manuscript posted online 30 January 2012.
  • Copyright © 2012, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.
    1. Borgianni L,
    2. et al
    . 2011. Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 55:140–145.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    CLSI. 2010. Performance standards for antimicrobial susceptibility testing; 20th information supplement (June 2010 update). M100-S20-U. Clinical and Laboratory Standards Institute, Wayne, PA.
  3. 3.↵
    1. Collis CM,
    2. Hall RM
    . 1992. Site-specific deletion and rearrangement of integron insert genes catalyzed by the integron DNA integrase. J. Bacteriol. 174:1574–1585.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Cornaglia G,
    2. Giamarellou H,
    3. Rossolini GM
    . 2011. Metallo-beta-lactamases: a last frontier for beta-lactams? Lancet Infect. Dis. 11:381–393.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Da Silva GJ,
    2. et al
    . 2002. Molecular characterization of bla(IMP-5), a new integron-borne metallo-beta-lactamase gene from an Acinetobacter baumannii nosocomial isolate in Portugal. FEMS Microbiol. Lett. 215:33–39.
    OpenUrlPubMedWeb of Science
  6. 6.↵
    1. Docquier JD,
    2. et al
    . 2003. IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate. Antimicrob. Agents Chemother. 47:1522–1528.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Gupta V
    . 2009. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin. Invest. Drugs 17:131–143.
    OpenUrl
  8. 8.↵
    1. Iyobe S,
    2. et al
    . 2002. Detection of a variant metallo-beta-lactamase, IMP-10, from two unrelated strains of Pseudomonas aeruginosa and an Alcaligenes xylosoxidans strain. Antimicrob. Agents Chemother. 46:2014–2016.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Jacoby GA
    . 1974. Properties of R plasmids determining gentamicin resistance by acetylation in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 6:239–252.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Jovcic B,
    2. et al
    . 2011. Emergence of NDM-1 metallo-β-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob. Agents Chemother. 55:3929–3931.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Kaufmann M
    . 1998. Pulsed-field gel electrophoresis. Methods Mol. Med. 15:33–50.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Kerr KG,
    2. Snelling AM
    . 2009. Pseudomonas aeruginosa: a formidable and ever-present adversary. J. Hosp. Infect. 73:338–344.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Kieser T
    . 1984. Factors affecting the isolation of CCC DNA from Streptomyces lividans and Escherichia coli. Plasmid 12:19–36.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.
    1. Laraki N,
    2. et al
    . 1999. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-beta-lactamase IMP-1 produced by Escherichia coli. Antimicrob. Agents Chemother. 43:902–906.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Mendes R,
    2. et al
    . 2007. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J. Clin. Microbiol. 45:544–547.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Mendes RE,
    2. et al
    . 2004. Integron carrying a novel metallo-β-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6′)-30/aac(6′)-Ib′: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 48:4693–4702.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Nikaido H
    . 1989. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob. Agents Chemother. 33:1831–1836.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Nordmann P,
    2. Poirel P,
    3. Carrer A,
    4. Toleman MA,
    5. Walsh T
    . 2011. How to detect NDM-1 producers. J. Clin. Microbiol. 49:718–721.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Pellegrini C,
    2. et al
    . 2009. Identification of bla(IMP-22) in Pseudomonas spp. in urban wastewater and nosocomial environments: biochemical characterization of a new IMP metallo-enzyme variant and its genetic location. J. Antimicrob. Chemother. 63:901–908.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Poirel L,
    2. Le Thomas I,
    3. Naas T,
    4. Karim A,
    5. Nordmann N
    . 2000. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 44:622–632.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Poirel L,
    2. Rodriguez-Martinez JM,
    3. Al Naiemi N,
    4. Debets-Ossenkopp YJ,
    5. Nordmann P
    . 2010. Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. Antimicrob. Agents Chemother. 54:2420–2424.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Rodriguez-Martinez JM,
    2. Poirel L,
    3. Nordmann P
    . 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4783–4788.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Tenover FC,
    2. et al
    . 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233–2239.
    OpenUrlFREE Full Text
  24. 24.↵
    1. Trias J,
    2. Nikaido H
    . 1990. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:52–57.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Yano H,
    2. et al
    . 2001. Plasmid-encoded metallo-beta-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob. Agents Chemother. 45:1343–1348.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Yong D,
    2. et al
    . 2007. A novel sub-group metallo-β-lactamase (MBL), AIM-1 emerges in Pseudomonas aeruginosa (PSA) from Australia, abstr C1-593, p 75. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
  27. 27.↵
    1. Zhao WH,
    2. Hi ZQ
    . 2010. Beta lactamases identified in clinical isolates of Pseudomonas aeruginosa. Crit. Rev. Microbiol. 36:245–258.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Zilberberg MD,
    2. Chen J,
    3. Mody SH,
    4. Ramsey AM,
    5. Shorr AF
    . 2010. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm. Med. 10:45.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
IMP-29, a Novel IMP-Type Metallo-β-Lactamase in Pseudomonas aeruginosa
Katy Jeannot, Laurent Poirel, Marjorie Robert-Nicoud, Pascal Cholley, Patrice Nordmann, Patrick Plésiat
Antimicrobial Agents and Chemotherapy Mar 2012, 56 (4) 2187-2190; DOI: 10.1128/AAC.05838-11

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
IMP-29, a Novel IMP-Type Metallo-β-Lactamase in Pseudomonas aeruginosa
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
IMP-29, a Novel IMP-Type Metallo-β-Lactamase in Pseudomonas aeruginosa
Katy Jeannot, Laurent Poirel, Marjorie Robert-Nicoud, Pascal Cholley, Patrice Nordmann, Patrick Plésiat
Antimicrobial Agents and Chemotherapy Mar 2012, 56 (4) 2187-2190; DOI: 10.1128/AAC.05838-11
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596